Experimental models of fatty liver diseases: Status and appraisal
- 주제(기타) Gastroenterology & Hepatology
- 설명문(일반) [Wang, Hua; Shen, Haiyuan] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, Hefei, Peoples R China; [Wang, Hua; Shen, Haiyuan] Anhui Med Univ, Inflammat & Immune Mediated Dis Lab Anhui Prov, Hefei, Peoples R China; [Seo, Wonhyo] Ewha Womans Univ, Coll Pharm, Lab Hepatotox, Seoul, South Korea; [Hwang, Seonghwan] Pusan Natl Univ, Res Inst Drug Dev, Busan, South Korea; [Hwang, Seonghwan] Pusan Natl Univ, Coll Pharm, Busan, South Korea; [Wang, Hua] Anhui Med Univ, Affiliated Hosp 1, Dept Oncol, 218 Jixi Rd, Hefei 230036, Peoples R China
- 등재 SCIE, SCOPUS
- OA유형 gold, Green Accepted
- 발행기관 JOHN WILEY & SONS LTD
- 발행년도 2023
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000208641
- 본문언어 영어
- Published As https://doi.org/10.1097/HC9.0000000000000200
- PubMed 37378635
초록/요약
Fatty liver diseases, including alcohol-associated liver disease (ALD) and nonalcoholic fatty liver disease nonalcoholic fatty liver disease (NAFLD), affect a large number of people worldwide and become one of the major causes of end-stage liver disease, such as liver cirrhosis and hepatocellular carcinoma (HCC). Unfortunately, there are currently no approved pharmacological treatments for ALD or NAFLD. This situation highlights the urgent need to explore new intervention targets and discover effective therapeutics for ALD and NAFLD. The lack of properly validated preclinical disease models is a major obstacle to the development of clinical therapies. ALD and NAFLD models have been in the development for decades, but there are still no models that recapitulate the full spectrum of ALD and NAFLD. Throughout this review, we summarize the current in vitro and in vivo models used for research on fatty liver diseases and discuss the advantages and limitations of these models.
more